The biotech provided an update after the stock market closed Thursday, telling investors that it had been unable to align ...
Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid ...
Kezar Life Sciences, Inc. (Nasdaq: KZR, the Company), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today ...
The SURPASS study is enrolling patients at research sites across the U.S. and EuropeELA026 targets signal regulatory proteins (SIRP) as a novel ...
The company reported that as of September 30, 2025, its cash, cash equivalents and marketable securities totaled approximately $90.2 million. Kezar’s Board of Directors has also extended its limited ...
IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through IND-enabling studies ...
Crawford, a medical oncologist at Duke Cancer Center and Duke Cancer Center Thoracic Clinic in Durham, North Carolina, ...
Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy; JADE101 is an investigational, p ...
Kezar Life Sciences (KZR) announced regulatory updates and the initiation of a process to explore a full range of strategic alternatives focused ...
Stocktwits on MSN
Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive
Kezar Life Sciences (KZR) shares rallied 47% on Friday afternoon despite analyst downgrades and price target cuts. Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences to ‘Hold’ from ‘Buy’ ...
Shares of Ovid Therapeutics OVID rallied 39.2% primarily driven by the encouraging top-line data readout from an early-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback